Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give a "Moderate Buy" consensus for RADX from four covering firms (1 sell, 2 buy, 1 strong buy) with an average 12‑month price target of $14.00.
• Shares are trading near the low end of their 52‑week range (opened at $4.48; 52‑week low $3.62, high $16.25) and the company reported weak quarterly results (EPS of <$1.58> and revenue of $0.46M).
• Several institutional investors built new or larger positions in the fourth quarter, notably HSBC (~$1.0M stake) and smaller new stakes from Virtu, Jane Street and Marex, while PNC doubled its holding.

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.00.

RADX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Radiopharm Theranostics to a "strong sell" rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Radiopharm Theranostics in a research note on Thursday, January 22nd. Finally, B. Riley Financial reaffirmed a "buy" rating and set a $16.00 target price (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th.

Radiopharm Theranostics Stock Up 3.0%

Shares of NASDAQ RADX opened at $4.48 on Thursday. Radiopharm Theranostics has a fifty-two week low of $3.62 and a fifty-two week high of $16.25. The company has a 50 day simple moving average of $4.78 and a two-hundred day simple moving average of $5.15.

Radiopharm Theranostics (NASDAQ:RADX - Get Free Report) last announced its earnings results on Wednesday, January 28th. The company reported ($1.58) earnings per share for the quarter. The business had revenue of $0.46 million for the quarter.

Hedge Funds Weigh In On Radiopharm Theranostics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC bought a new position in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $1,007,000. Virtu Financial LLC bought a new stake in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $76,000. Jane Street Group LLC bought a new stake in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $76,000. Marex Group plc bought a new stake in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $54,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Radiopharm Theranostics by 100.0% during the third quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company's stock valued at $88,000 after acquiring an additional 8,000 shares in the last quarter.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company's research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.